{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:22Z","timestamp":1790882422651,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jare.2026.01.047","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:50:56Z","timestamp":1768776656000},"page":"589-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance"],"prefix":"10.1016","volume":"88","author":[{"given":"Xiaoyu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.01.047_b0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"10.1016\/j.jare.2026.01.047_b0010","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian cancer prevention and screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jare.2026.01.047_b0020","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jare.2026.01.047_b0030","first-page":"9950","article-title":"Metabolic reprogramming in epithelial ovarian cancer","volume":"13","author":"Nantasupha","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jare.2026.01.047_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1231460","article-title":"Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer","volume":"13","author":"Yan","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0040","first-page":"938","article-title":"Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance","volume":"55","author":"Yue","year":"2023","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0045","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","article-title":"Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells","volume":"13","author":"Tan","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-018-0424-x","article-title":"DNA damage repair in ovarian cancer: unlocking the heterogeneity","volume":"11","author":"Gee","year":"2018","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.jare.2026.01.047_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dnarep.2019.06.005","article-title":"DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies","volume":"80","author":"Mirza-Aghazadeh-Attari","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.jare.2026.01.047_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1284853","article-title":"Research progress on the mechanism of glycolysis in ovarian cancer","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cac2.12274","article-title":"The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells","volume":"42","author":"Wang","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.jare.2026.01.047_b0070","article-title":"Noncoding RNAs in the glycolysis of ovarian cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.01.047_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156121","article-title":"Berberine modulates ovarian cancer autophagy and glycolysis through the LINC01123\/P65\/MAPK10 signaling axis","volume":"135","author":"Yan","year":"2024","journal-title":"Phytomedicine"},{"issue":"7\u20138","key":"10.1016\/j.jare.2026.01.047_b0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s10495-024-01962-5","article-title":"MARCH5 promotes aerobic glycolysis to facilitate ovarian cancer progression via ubiquitinating MPC1","volume":"29","author":"Xu","year":"2024","journal-title":"Apoptosis"},{"issue":"5\u20136","key":"10.1016\/j.jare.2026.01.047_b0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14712\/fb2023069050163","article-title":"MiR-19a-3p promotes aerobic glycolysis in ovarian cancer cells via IGFBP3\/PI3K\/AKT pathway","volume":"69","author":"Du","year":"2023","journal-title":"Folia Biol (Praha)"},{"key":"10.1016\/j.jare.2026.01.047_b0090","article-title":"Tankyrase promotes aerobic glycolysis and proliferation of ovarian cancer through activation of Wnt\/\u03b2-catenin signaling","volume":"2019","author":"Yang","year":"2019","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4149\/neo_2017_211","article-title":"miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic glycolysis by targeting LDHA","volume":"64","author":"Han","year":"2017","journal-title":"Neoplasma"},{"key":"10.1016\/j.jare.2026.01.047_b0100","article-title":"Targeting oxidative phosphorylation as an approach for the treatment of ovarian cancer","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2026.01.047_b0105","doi-asserted-by":"crossref","unstructured":"Nayak AP, Kapur A, Barroilhet L, Patankar MS: Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers (Basel) 2018, 10(9).","DOI":"10.3390\/cancers10090337"},{"issue":"11","key":"10.1016\/j.jare.2026.01.047_b0110","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/humrep\/dead177","article-title":"Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction","volume":"38","author":"Smits","year":"2023","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0115","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/0008-5472.CAN-20-1488","article-title":"Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055041","article-title":"Ovarian cancer and glutamine metabolism","volume":"24","author":"Fasoulakis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2026.01.047_b0125","article-title":"New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","article-title":"PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers","volume":"29","author":"Gentric","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s43018-020-00160-x","article-title":"Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma","volume":"2","author":"Wu","year":"2021","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042170","article-title":"Fatty acid metabolism in ovarian cancer: therapeutic implications","volume":"23","author":"Yoon","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jare.2026.01.047_b0145","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.7150\/thno.70194","article-title":"SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells","volume":"12","author":"Xuan","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-024-02009-8","article-title":"ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189052","article-title":"The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models","volume":"1879","author":"Tadi\u0107","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/ijgc-2022-003704","article-title":"New therapies for clear cell ovarian carcinoma","volume":"33","author":"Stewart","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0170","article-title":"Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1\u03b1 and tumor progression of clear cell ovarian cancer","volume":"5","author":"Mori","year":"2024","journal-title":"Cell Rep Med"},{"issue":"16","key":"10.1016\/j.jare.2026.01.047_b0175","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-22-3646","article-title":"Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0180","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0185","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.jare.2026.01.047_b0190","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13062-023-00420-7","article-title":"N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression","volume":"18","author":"Gan","year":"2023","journal-title":"Biol Direct"},{"key":"10.1016\/j.jare.2026.01.047_b0200","doi-asserted-by":"crossref","first-page":"14634","DOI":"10.1038\/ncomms14634","article-title":"MICU1 drives glycolysis and chemoresistance in ovarian cancer","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0205","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00404-019-05100-4","article-title":"Follicle-stimulating hormone promoted pyruvate kinase isozyme type M2-induced glycolysis and proliferation of ovarian cancer cells","volume":"299","author":"Li","year":"2019","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1142\/S0192415X24500356","article-title":"Xanthohumol promotes Skp2 ubiquitination leading to the inhibition of glycolysis and tumorigenesis in ovarian cancer","volume":"52","author":"He","year":"2024","journal-title":"Am J Chin Med"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-022-02252-1","article-title":"TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1\u03b1 degradation","volume":"41","author":"Chen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060813","article-title":"Hexokinase 2 regulates ovarian cancer cell migration, invasion and stemness via FAK\/ERK1\/2\/MMP9\/NANOG\/SOX9 signaling cascades","volume":"11","author":"Siu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.01.047_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2018.10.014","article-title":"miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells","volume":"661","author":"Lu","year":"2019","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"10.1016\/j.jare.2026.01.047_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114551","article-title":"Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer","volume":"43","author":"Frisbie","year":"2024","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0235","article-title":"Active DNA demethylase, TET1, increases oxidative phosphorylation and sensitizes ovarian cancer stem cells to mitochondrial complex I inhibitor","volume":"13","author":"Chen","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"11","key":"10.1016\/j.jare.2026.01.047_b0240","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1002\/jcp.26540","article-title":"Sideroxylin (Callistemon lanceolatus) suppressed cell proliferation and increased apoptosis in ovarian cancer cells accompanied by mitochondrial dysfunction, the generation of reactive oxygen species, and an increase of lipid peroxidation","volume":"233","author":"Park","year":"2018","journal-title":"J Cell Physiol"},{"issue":"8","key":"10.1016\/j.jare.2026.01.047_b0245","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.21873\/anticanres.16515","article-title":"Ovarian clear cell carcinoma: genomic characterization, pathogenesis and targeted therapy","volume":"43","author":"Xie","year":"2023","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.jare.2026.01.047_b0250","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/fon.15.45","article-title":"Molecular pathogenesis of ovarian clear cell carcinoma","volume":"11","author":"Gounaris","year":"2015","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0255","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/uog.24904","article-title":"Imaging in gynecological disease (24): clinical and ultrasound characteristics of ovarian mature cystic teratomas","volume":"60","author":"Heremans","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.jare.2026.01.047_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5920","article-title":"Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study","volume":"349","author":"Van Calster","year":"2014","journal-title":"Bmj"},{"issue":"7727","key":"10.1016\/j.jare.2026.01.047_b0265","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-018-0597-x","article-title":"IRE1\u03b1-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity","volume":"562","author":"Song","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.01.047_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0275","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","article-title":"Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis","volume":"41","author":"Zhou","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.01.047_b0280","first-page":"2018","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jare.2026.01.047_b0285","doi-asserted-by":"crossref","unstructured":"Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, et al. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 2023, 26(2):106020.","DOI":"10.1016\/j.isci.2023.106020"},{"issue":"20","key":"10.1016\/j.jare.2026.01.047_b0290","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-19-3971","article-title":"Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers","volume":"80","author":"Shen","year":"2020","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0295","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ymthe.2022.12.011","article-title":"Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma","volume":"31","author":"Raninga","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.jare.2026.01.047_b0300","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-19-1999","article-title":"Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance","volume":"80","author":"Mukherjee","year":"2020","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2026.01.047_b0305","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0310","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cell.2024.10.047","article-title":"ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jare.2026.01.047_b0315","article-title":"ASS1 enhances anoikis resistance via AMPK\/CPT1A-mediated fatty acid metabolism in ovarian cancer","volume":"217082","author":"Feng","year":"2024","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.jare.2026.01.047_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.100984","article-title":"Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA\/ROCK signalling pathway","volume":"14","author":"Han","year":"2024","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.jare.2026.01.047_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176639","article-title":"Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism","volume":"975","author":"Lu","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jare.2026.01.047_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114282","article-title":"Therapeutic potential of targeting mitochondrial dynamics in cancer","volume":"182","author":"Rodrigues","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0335","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s42003-025-07720-w","article-title":"CPT1A-mediated MFF succinylation promotes stemness maintenance in ovarian cancer stem cells","volume":"8","author":"Zhu","year":"2025","journal-title":"Commun Biol"},{"issue":"7","key":"10.1016\/j.jare.2026.01.047_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071882","article-title":"Glutathione in ovarian cancer: a double-edged sword","volume":"19","author":"Nunes","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9\u201310","key":"10.1016\/j.jare.2026.01.047_b0345","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s10495-024-01985-y","article-title":"Targeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis","volume":"29","author":"Luo","year":"2024","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0350","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12967-023-04136-0","article-title":"CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer","volume":"21","author":"Zhang","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010587","article-title":"Role of SLC7A11\/xCT in ovarian cancer","volume":"25","author":"Fantone","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jare.2026.01.047_b0360","doi-asserted-by":"crossref","unstructured":"Compton SLE, Grieco JP, Gollamudi B, Bae E, Van Mullekom JH, Schmelz EM. Metabolic reprogramming of ovarian cancer spheroids during adhesion. Cancers (Basel) 2022, 14(6).","DOI":"10.3390\/cancers14061399"},{"issue":"Pt 2","key":"10.1016\/j.jare.2026.01.047_b0365","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semcancer.2022.03.004","article-title":"Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment","volume":"86","author":"Monavarian","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"18","key":"10.1016\/j.jare.2026.01.047_b0370","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"issue":"7538","key":"10.1016\/j.jare.2026.01.047_b0375","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jare.2026.01.047_b0380","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.7150\/ijbs.71571","article-title":"GRP75-faciliated mitochondria-associated ER membrane (MAM) integrity controls cisplatin-resistance in ovarian cancer patients","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0385","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12967-024-04980-8","article-title":"ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis","volume":"22","author":"Gong","year":"2024","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0390","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1535-7163.MCT-23-0550","article-title":"Mitochondrial and cytosolic one-carbon metabolism is a targetable metabolic vulnerability in cisplatin-resistant ovarian cancer","volume":"23","author":"Wallace-Povirk","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2026.01.047_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116093","volume":"37","author":"Wallace-Povirk","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jare.2026.01.047_b0400","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2350-9-58","article-title":"Novel de novo BRCA2 mutation in a patient with a family history of breast cancer","volume":"9","author":"Hansen","year":"2008","journal-title":"BMC Med Genet"},{"issue":"8","key":"10.1016\/j.jare.2026.01.047_b0405","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.jare.2026.01.047_b0410","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jare.2026.01.047_b0415","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.18632\/oncotarget.3126","article-title":"JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer","volume":"6","author":"Qiu","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0420","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1038\/s41467-018-04987-y","article-title":"FABP4 as a key determinant of metastatic potential of ovarian cancer","volume":"9","author":"Gharpure","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0425","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5664","article-title":"ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway","volume":"65","author":"Xu","year":"2024","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0430","first-page":"2331","article-title":"ARID1a gene as a potential early marker to tackle endometriosis-associated ovarian cancer","volume":"15","author":"Kordowitzki","year":"2023","journal-title":"Aging Dis"},{"issue":"10","key":"10.1016\/j.jare.2026.01.047_b0435","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s11427-021-2048-2","article-title":"Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth","volume":"65","author":"Pei","year":"2022","journal-title":"Sci China Life Sci"},{"issue":"27","key":"10.1016\/j.jare.2026.01.047_b0440","doi-asserted-by":"crossref","first-page":"41637","DOI":"10.18632\/oncotarget.9317","article-title":"Altered glutamine metabolism in platinum resistant ovarian cancer","volume":"7","author":"Hudson","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0445","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol Oncol"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0450","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3892\/or.2014.3297","article-title":"Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer","volume":"32","author":"Li","year":"2014","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0455","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1038\/s41598-025-90963-8","article-title":"Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jare.2026.01.047_b0460","first-page":"2586","article-title":"Endometrioid ovarian carcinoma landscape: pathological and molecular characterization","volume":"18","author":"de Nonneville","year":"2024","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0465","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12905-022-01917-5","article-title":"Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study","volume":"22","author":"Ishizaka","year":"2022","journal-title":"BMC Womens Health"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0470","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/PGP.0000000000000564","article-title":"Ovarian endometrioid carcinoma misdiagnosed as mucinous carcinoma: an underrecognized problem","volume":"38","author":"Woodbeck","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0475","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13048-023-01100-w","article-title":"Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?","volume":"16","author":"Hu","year":"2023","journal-title":"J Ovarian Res"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0480","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/humrep\/deae043","article-title":"Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma","volume":"39","author":"Linder","year":"2024","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/path.6407","article-title":"Cellular origins of mucinous ovarian carcinoma","volume":"266","author":"Meagher","year":"2025","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.jare.2026.01.047_b0490","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1055\/a-0717-5411","article-title":"Low-grade serous ovarian carcinoma","volume":"78","author":"Ricciardi","year":"2018","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0495","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ajo.13105","article-title":"Low-grade serous ovarian carcinoma: A comprehensive literature review","volume":"60","author":"Goulding","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061506","article-title":"Development of low-grade serous ovarian carcinoma from benign ovarian serous cystadenoma cells","volume":"14","author":"Dey","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jare.2026.01.047_b0505","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-025-02295-w","article-title":"Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer","volume":"24","author":"Lu","year":"2025","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0515","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12967-023-04349-3","article-title":"A traditional gynecological medicine inhibits ovarian cancer progression and eliminates cancer stem cells via the LRPPRC-OXPHOS axis","volume":"21","author":"Jiang","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0520","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3892\/ijo.2017.3891","article-title":"Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma invitro","volume":"50","author":"Sato","year":"2017","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0525","article-title":"Polyurea dendrimer folate-targeted nanodelivery of l-buthionine sulfoximine as a tool to tackle ovarian cancer chemoresistance","volume":"9","author":"Cruz","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"10.1016\/j.jare.2026.01.047_b0530","first-page":"1731","article-title":"Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation","volume":"38","author":"Ong","year":"2011","journal-title":"Int J Oncol"},{"issue":"41","key":"10.1016\/j.jare.2026.01.047_b0535","doi-asserted-by":"crossref","first-page":"22126","DOI":"10.1002\/anie.202015200","article-title":"Enabling clinical technologies for hyperpolarized (129) xenon magnetic resonance imaging and spectroscopy","volume":"60","author":"Khan","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"10.1016\/j.jare.2026.01.047_b0540","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tins.2020.03.006","article-title":"Imaging brain metabolism using hyperpolarized (13)C magnetic resonance spectroscopy","volume":"43","author":"Le Page","year":"2020","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jare.2026.01.047_b0545","doi-asserted-by":"crossref","unstructured":"Zhang M, Chen Z, Wang Y, Zhao H, Du Y: The role of cancer-associated fibroblasts in ovarian cancer. Cancers (Basel) 2022, 14(11)","DOI":"10.3390\/cancers14112637"},{"issue":"1","key":"10.1016\/j.jare.2026.01.047_b0550","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12929-022-00888-x","article-title":"Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-\u03baB and TGF-\u03b22 signaling","volume":"29","author":"Lin","year":"2022","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.jare.2026.01.047_b0555","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021224","article-title":"Ovarian cancer: a landscape of mitochondria with emphasis on mitochondrial dynamics","volume":"24","author":"De Rasmo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0560","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/path.6006","article-title":"The proteome of clear cell ovarian carcinoma","volume":"258","author":"Ji","year":"2022","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.jare.2026.01.047_b0565","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: a clinical and molecular perspective","volume":"31","author":"Iida","year":"2021","journal-title":"Int J Gynecol Cancer"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:07:51Z","timestamp":1790784471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012322600072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":113,"alternative-id":["S209012322600072X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.01.047","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}